TITLE

Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study

AUTHOR(S)
Schweighofer, Carmen; Tuchscherer, Armin; Sperka, Sabine; Meyer, Thorsten; Rattel, Benno; Stein, Sandra; Ismail, Semra; Elter, Thomas; Staib, Peter; Reiser, Marcel; Hallek, Michael
PUB. DATE
December 2012
SOURCE
Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2367
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1D09C3 is a human monoclonal IgG4-type antibody against human leukocyte antigen-DR (HLA-DR) which has demonstrated pro-apoptotic activity against lymphoid tumors in vitro and in vivo. We report results from a phase I dose-escalation study which aimed to identify tolerated dosing, and the pharmacokinetic and pharmacodynamic profile of 1D09C3. Fourteen patients with relapsed/refractory B cell type leukemia/lymphoma were treated and followed after up to 4 weekly infusions of 1D09C3, administered in 6 dose levels at 0.25-8 mg/kg/day. Treatment was tolerated well with mostly mild side effects. The most common grade III-IV toxicities were hematological events observed in 4 patients. In one patient, treated at 8.0 mg/kg/day, a dose limiting toxicity occurred, identified as an invasive catheter-related infection. Adverse events resolved completely without long-term sequelae. 1D09C3 reduced peripheral blood B cells and monocytes by a median of 73-81 % in all patients, with a nadir reached 30-60 min after infusion and sustained for <96 h. Granulocytes and natural killer cells predominantly increased with variable time courses. Pharmacokinetic assessments showed detectable drug concentrations at doses 4-8 mg/kg/day and a terminal half-life of 0.7-7.9 h. Effective saturation of HLA-DR on peripheral blood B cells/monocytes was achieved, varying consistently with available serum concentrations and the cell-reducing activity of 1D09C3. In summary, 1D09C3 could be administered safely in patients with advanced B cell malignancies. Pharmacodynamic studies demonstrated a strong dose dependent but transient reduction of peripheral blood B cells and monocytes, consistent with a short drug serum availability.
ACCESSION #
83594442

 

Related Articles

  • Fatal infusion reaction with ARZERRA in Canada.  // Reactions Weekly;Aug2014, Vol. 1515 Issue 1, p2 

    The article reports on the letter issued by pharmaceutical company GlaxoSmithKline (GSK) and Health Canada about the occurrence of fatal infusion reaction in a patient with chronic lymphocytic leukaemia (CLL) who received intravenous ofatumumab (ARZERRA) therapy.

  • Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Perumal, Jai S; Foo, Farng; Cook, Perry; Khan, Omar // Multiple Sclerosis Journal;Aug2012, Vol. 18 Issue 8, p1197 

    Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines...

  • HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic... Michallet, Mauricette; Archimbaud, Eric // Annals of Internal Medicine;1/31/96, Vol. 124 Issue 3, p311 

    Characterizes the outcomes of HLA-identical sibling bone marrow transplantation for chronic lymphocytic leukemia (CLL) in patients younger than 60 years old. Pretransplant conditioning; Prophylaxis for graft-versus-host disease; Hematologic remission of half of the patient group; Feasibility of...

  • Rituximab: A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Keating, Gillian M. // Drugs;2010, Vol. 70 Issue 11, p1445 

    Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukaemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. The addition of...

  • Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia. Stagno, Fabio; Vigneri, Paolo; Del Fabro, Vittorio; Fidilio, Anna; Spina, Paolo; Massimino, Michele; Messina, Angelo; Di Raimondo, Francesco // Acta Haematologica;Oct2010, Vol. 124 Issue 2, p103 

    The article discusses a case of an elderly man with refractory B cell chronic lymphocytic leukemia (B-CLL) that was not treated by dasatinib (DAS). Before the patient started receiving DAS, he was given 5 other lines of treatment for his hematological disease, which include chlorambucil and...

  • Obinutuzumab Injection.  // AHFS Consumer Medication Information;Feb2020, p1 

    Obinutuzumab injection is used with chlorambucil (Leukeran) to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Obinutuzumab injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells.

  • Ofatumumab Injection.  // AHFS Consumer Medication Information;Feb2020, p1 

    Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells) in adults who have not gotten better after treatment with fludarabine (Fludara) and alemtuzumab (Campath). Ofatumumab injection is in a class of medications called monoclonal...

  • Rituximab for the Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia. Hagemeister, Fredrick // Drugs;2010, Vol. 70 Issue 3, p261 

    Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-cell-derived haematological malignancies. Rituximab, in combination with chemotherapy, has significantly improved survival outcomes for patients diagnosed with follicular lymphoma (FL) and diffuse large...

  • Proteasome inhibition enhances HLA-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Stockmeyer, B.; Gramatzki, M.; Repp, R. // Cancer Cell International;2004 Supplement 1, Vol. 4, pS21 

    The article shows that proteasome inhibition enhances human leukocyte antigen (HLA)-class-II antibody-dependent polymorphonuclear cell mediated cytotoxicity against B-cell lymphoma. Although polymorphonuclear granulocytes (PMN) mediated significant lysis with HLA-class-II mAb, no significant...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics